Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) Receives Consensus Rating of “Moderate Buy” from Analysts

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) has been given an average recommendation of “Moderate Buy” by the eleven brokerages that are currently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, nine have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $37.6667.

Several brokerages have issued reports on TEVA. Piper Sandler reaffirmed an “overweight” rating and set a $41.00 target price (up from $40.00) on shares of Teva Pharmaceutical Industries in a research note on Wednesday, March 4th. Jefferies Financial Group boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, January 6th. Barclays boosted their price target on shares of Teva Pharmaceutical Industries from $35.00 to $38.00 and gave the company an “overweight” rating in a research report on Friday, January 30th. Bank of America boosted their price target on shares of Teva Pharmaceutical Industries from $29.00 to $32.00 and gave the company a “buy” rating in a research report on Tuesday, December 9th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Teva Pharmaceutical Industries in a research report on Wednesday, January 21st.

Teva Pharmaceutical Industries Trading Down 1.6%

Shares of TEVA opened at $29.34 on Wednesday. Teva Pharmaceutical Industries has a 52-week low of $12.47 and a 52-week high of $37.35. The company has a quick ratio of 0.80, a current ratio of 1.04 and a debt-to-equity ratio of 1.89. The firm’s fifty day moving average is $32.04 and its two-hundred day moving average is $28.01. The stock has a market cap of $33.74 billion, a PE ratio of 24.45, a price-to-earnings-growth ratio of 10.13 and a beta of 0.76.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion for the quarter, compared to analysts’ expectations of $4.36 billion. During the same quarter in the previous year, the company posted $0.71 EPS. The firm’s quarterly revenue was up 11.4% on a year-over-year basis. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. Research analysts forecast that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current fiscal year.

Insider Activity

In other news, EVP Eliyahu Sharon Kalif sold 345,810 shares of the business’s stock in a transaction dated Thursday, February 26th. The shares were sold at an average price of $33.64, for a total transaction of $11,633,048.40. Following the transaction, the executive vice president owned 57,478 shares of the company’s stock, valued at approximately $1,933,559.92. The trade was a 85.75% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Mark Sabag sold 62,102 shares of the business’s stock in a transaction dated Tuesday, March 17th. The shares were sold at an average price of $30.14, for a total transaction of $1,871,754.28. Following the transaction, the insider directly owned 224,940 shares in the company, valued at approximately $6,779,691.60. The trade was a 21.64% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 920,901 shares of company stock worth $30,056,789. Insiders own 0.55% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of the company. Phoenix Financial Ltd. raised its holdings in Teva Pharmaceutical Industries by 9.4% in the 3rd quarter. Phoenix Financial Ltd. now owns 41,295,244 shares of the company’s stock valued at $834,164,000 after buying an additional 3,533,800 shares during the period. National Pension Service raised its holdings in Teva Pharmaceutical Industries by 24.2% in the 3rd quarter. National Pension Service now owns 2,073,293 shares of the company’s stock valued at $41,881,000 after buying an additional 404,526 shares during the period. Public Sector Pension Investment Board raised its holdings in Teva Pharmaceutical Industries by 11.5% in the 3rd quarter. Public Sector Pension Investment Board now owns 670,467 shares of the company’s stock valued at $13,543,000 after buying an additional 69,000 shares during the period. Oak Harvest Investment Services purchased a new stake in Teva Pharmaceutical Industries in the 3rd quarter valued at about $1,010,000. Finally, Harel Insurance Investments & Financial Services Ltd. raised its holdings in Teva Pharmaceutical Industries by 12.9% in the 3rd quarter. Harel Insurance Investments & Financial Services Ltd. now owns 37,696,690 shares of the company’s stock valued at $761,455,000 after buying an additional 4,306,363 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.